Review





Similar Products

mouse embryonic fibroblast cell line sto feeder cells  (ATCC)
93
ATCC mouse embryonic fibroblast cell line sto feeder cells
Mouse Embryonic Fibroblast Cell Line Sto Feeder Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+fibroblast+cell+line+sto/STO+mouse+fibroblast+cells%2C+STO/pmc11949452-56-7-15
Average 93 stars, based on 1 article reviews
mouse embryonic fibroblast cell line sto feeder cells - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
murine fibroblast cell line sto  (ATCC)
94
ATCC murine fibroblast cell line sto
Differentiation of ES-D3 cells decreases their efficacy to prevent the development of implanted lung tumors. ( A ) The schematic depiction of immunization regimen. Male and female C57BL/6 mice were immunized twice with 1 × PBS (vehicle control), parental ES-D3 cells + <t>STO</t> <t>fibroblasts</t> expressing GM-CSF (STO/GM-CSF) or differentiated ES-D3 cells + STO/GM-CSF prior to subcutaneous challenge with LLC cells (0.15 × 10 6 ) at Day 14. Tumor-free mice were challenged again with LLC cells (0.15 × 10 6 ) at day 72. ( B ) The percentages of tumor-free male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender) following the first LLC injection are shown. Log-rank test; Asterisk (*) indicates p < 0.05; Asterisks (**) indicate p < 0.01; Asterisks (***) indicate p < 0.001. ( C ) Kaplan–Meier survival curve demonstrates the probability of survival in male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender). Log-rank test; Asterisks (***) indicate p < 0.001. ( D ) Twenty-eight days after the second LLC challenge, the percentages of tumor-bearing mice in mice immunized with parental ES-D3 cells + STO/GM-CSF (n = 8) or differentiated ES-D3 cells + STO/GM-CSF (n = 2) were determined.
Murine Fibroblast Cell Line Sto, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+fibroblast+cell+line+sto/STO%3B+Embryonic+Fibroblast%3B+Mouse/pmc11685895-201-0-5
Average 94 stars, based on 1 article reviews
murine fibroblast cell line sto - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
sto mouse embryonic fibroblast cell line  (ATCC)
95
ATCC sto mouse embryonic fibroblast cell line
Differentiation of ES-D3 cells decreases their efficacy to prevent the development of implanted lung tumors. ( A ) The schematic depiction of immunization regimen. Male and female C57BL/6 mice were immunized twice with 1 × PBS (vehicle control), parental ES-D3 cells + <t>STO</t> <t>fibroblasts</t> expressing GM-CSF (STO/GM-CSF) or differentiated ES-D3 cells + STO/GM-CSF prior to subcutaneous challenge with LLC cells (0.15 × 10 6 ) at Day 14. Tumor-free mice were challenged again with LLC cells (0.15 × 10 6 ) at day 72. ( B ) The percentages of tumor-free male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender) following the first LLC injection are shown. Log-rank test; Asterisk (*) indicates p < 0.05; Asterisks (**) indicate p < 0.01; Asterisks (***) indicate p < 0.001. ( C ) Kaplan–Meier survival curve demonstrates the probability of survival in male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender). Log-rank test; Asterisks (***) indicate p < 0.001. ( D ) Twenty-eight days after the second LLC challenge, the percentages of tumor-bearing mice in mice immunized with parental ES-D3 cells + STO/GM-CSF (n = 8) or differentiated ES-D3 cells + STO/GM-CSF (n = 2) were determined.
Sto Mouse Embryonic Fibroblast Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+fibroblast+cell+line+sto/STO/pm35420127-95-18-25
Average 95 stars, based on 1 article reviews
sto mouse embryonic fibroblast cell line - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
mouse embryonic fibroblast mef cell line  (ATCC)
95
ATCC mouse embryonic fibroblast mef cell line
Differentiation of ES-D3 cells decreases their efficacy to prevent the development of implanted lung tumors. ( A ) The schematic depiction of immunization regimen. Male and female C57BL/6 mice were immunized twice with 1 × PBS (vehicle control), parental ES-D3 cells + <t>STO</t> <t>fibroblasts</t> expressing GM-CSF (STO/GM-CSF) or differentiated ES-D3 cells + STO/GM-CSF prior to subcutaneous challenge with LLC cells (0.15 × 10 6 ) at Day 14. Tumor-free mice were challenged again with LLC cells (0.15 × 10 6 ) at day 72. ( B ) The percentages of tumor-free male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender) following the first LLC injection are shown. Log-rank test; Asterisk (*) indicates p < 0.05; Asterisks (**) indicate p < 0.01; Asterisks (***) indicate p < 0.001. ( C ) Kaplan–Meier survival curve demonstrates the probability of survival in male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender). Log-rank test; Asterisks (***) indicate p < 0.001. ( D ) Twenty-eight days after the second LLC challenge, the percentages of tumor-bearing mice in mice immunized with parental ES-D3 cells + STO/GM-CSF (n = 8) or differentiated ES-D3 cells + STO/GM-CSF (n = 2) were determined.
Mouse Embryonic Fibroblast Mef Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+fibroblast+cell+line+sto/STO/pmc09054839-403-0-6
Average 95 stars, based on 1 article reviews
mouse embryonic fibroblast mef cell line - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
mouse embryonic fibroblast cell line sto  (ATCC)
94
ATCC mouse embryonic fibroblast cell line sto
Differentiation of ES-D3 cells decreases their efficacy to prevent the development of implanted lung tumors. ( A ) The schematic depiction of immunization regimen. Male and female C57BL/6 mice were immunized twice with 1 × PBS (vehicle control), parental ES-D3 cells + <t>STO</t> <t>fibroblasts</t> expressing GM-CSF (STO/GM-CSF) or differentiated ES-D3 cells + STO/GM-CSF prior to subcutaneous challenge with LLC cells (0.15 × 10 6 ) at Day 14. Tumor-free mice were challenged again with LLC cells (0.15 × 10 6 ) at day 72. ( B ) The percentages of tumor-free male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender) following the first LLC injection are shown. Log-rank test; Asterisk (*) indicates p < 0.05; Asterisks (**) indicate p < 0.01; Asterisks (***) indicate p < 0.001. ( C ) Kaplan–Meier survival curve demonstrates the probability of survival in male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender). Log-rank test; Asterisks (***) indicate p < 0.001. ( D ) Twenty-eight days after the second LLC challenge, the percentages of tumor-bearing mice in mice immunized with parental ES-D3 cells + STO/GM-CSF (n = 8) or differentiated ES-D3 cells + STO/GM-CSF (n = 2) were determined.
Mouse Embryonic Fibroblast Cell Line Sto, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+fibroblast+cell+line+sto/STO%3B+Embryonic+Fibroblast%3B+Mouse/pmc08284819-50-0-6
Average 94 stars, based on 1 article reviews
mouse embryonic fibroblast cell line sto - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
mouse embryonic fibroblast cell line called sto cells  (ATCC)
95
ATCC mouse embryonic fibroblast cell line called sto cells
Differentiation of ES-D3 cells decreases their efficacy to prevent the development of implanted lung tumors. ( A ) The schematic depiction of immunization regimen. Male and female C57BL/6 mice were immunized twice with 1 × PBS (vehicle control), parental ES-D3 cells + <t>STO</t> <t>fibroblasts</t> expressing GM-CSF (STO/GM-CSF) or differentiated ES-D3 cells + STO/GM-CSF prior to subcutaneous challenge with LLC cells (0.15 × 10 6 ) at Day 14. Tumor-free mice were challenged again with LLC cells (0.15 × 10 6 ) at day 72. ( B ) The percentages of tumor-free male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender) following the first LLC injection are shown. Log-rank test; Asterisk (*) indicates p < 0.05; Asterisks (**) indicate p < 0.01; Asterisks (***) indicate p < 0.001. ( C ) Kaplan–Meier survival curve demonstrates the probability of survival in male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender). Log-rank test; Asterisks (***) indicate p < 0.001. ( D ) Twenty-eight days after the second LLC challenge, the percentages of tumor-bearing mice in mice immunized with parental ES-D3 cells + STO/GM-CSF (n = 8) or differentiated ES-D3 cells + STO/GM-CSF (n = 2) were determined.
Mouse Embryonic Fibroblast Cell Line Called Sto Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+fibroblast+cell+line+sto/STO/pmc07916186-105-21-30
Average 95 stars, based on 1 article reviews
mouse embryonic fibroblast cell line called sto cells - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
mouse sim thioguanine ouabain resistant mouse fibroblast cell line sto fibroblasts  (ATCC)
93
ATCC mouse sim thioguanine ouabain resistant mouse fibroblast cell line sto fibroblasts
Differentiation of ES-D3 cells decreases their efficacy to prevent the development of implanted lung tumors. ( A ) The schematic depiction of immunization regimen. Male and female C57BL/6 mice were immunized twice with 1 × PBS (vehicle control), parental ES-D3 cells + <t>STO</t> <t>fibroblasts</t> expressing GM-CSF (STO/GM-CSF) or differentiated ES-D3 cells + STO/GM-CSF prior to subcutaneous challenge with LLC cells (0.15 × 10 6 ) at Day 14. Tumor-free mice were challenged again with LLC cells (0.15 × 10 6 ) at day 72. ( B ) The percentages of tumor-free male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender) following the first LLC injection are shown. Log-rank test; Asterisk (*) indicates p < 0.05; Asterisks (**) indicate p < 0.01; Asterisks (***) indicate p < 0.001. ( C ) Kaplan–Meier survival curve demonstrates the probability of survival in male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender). Log-rank test; Asterisks (***) indicate p < 0.001. ( D ) Twenty-eight days after the second LLC challenge, the percentages of tumor-bearing mice in mice immunized with parental ES-D3 cells + STO/GM-CSF (n = 8) or differentiated ES-D3 cells + STO/GM-CSF (n = 2) were determined.
Mouse Sim Thioguanine Ouabain Resistant Mouse Fibroblast Cell Line Sto Fibroblasts, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+fibroblast+cell+line+sto/STO+mouse+fibroblast+cells%2C+STO/pmc06565751__mmc1-97-9-18
Average 93 stars, based on 1 article reviews
mouse sim thioguanine ouabain resistant mouse fibroblast cell line sto fibroblasts - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
feeder cells are mouse fibroblasts cell lines  (ATCC)
93
ATCC feeder cells are mouse fibroblasts cell lines
Differentiation of ES-D3 cells decreases their efficacy to prevent the development of implanted lung tumors. ( A ) The schematic depiction of immunization regimen. Male and female C57BL/6 mice were immunized twice with 1 × PBS (vehicle control), parental ES-D3 cells + <t>STO</t> <t>fibroblasts</t> expressing GM-CSF (STO/GM-CSF) or differentiated ES-D3 cells + STO/GM-CSF prior to subcutaneous challenge with LLC cells (0.15 × 10 6 ) at Day 14. Tumor-free mice were challenged again with LLC cells (0.15 × 10 6 ) at day 72. ( B ) The percentages of tumor-free male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender) following the first LLC injection are shown. Log-rank test; Asterisk (*) indicates p < 0.05; Asterisks (**) indicate p < 0.01; Asterisks (***) indicate p < 0.001. ( C ) Kaplan–Meier survival curve demonstrates the probability of survival in male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender). Log-rank test; Asterisks (***) indicate p < 0.001. ( D ) Twenty-eight days after the second LLC challenge, the percentages of tumor-bearing mice in mice immunized with parental ES-D3 cells + STO/GM-CSF (n = 8) or differentiated ES-D3 cells + STO/GM-CSF (n = 2) were determined.
Feeder Cells Are Mouse Fibroblasts Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+fibroblast+cell+line+sto/STO+mouse+fibroblast+cells%2C+STO/us09701945-333-2-12
Average 93 stars, based on 1 article reviews
feeder cells are mouse fibroblasts cell lines - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

Image Search Results


Differentiation of ES-D3 cells decreases their efficacy to prevent the development of implanted lung tumors. ( A ) The schematic depiction of immunization regimen. Male and female C57BL/6 mice were immunized twice with 1 × PBS (vehicle control), parental ES-D3 cells + STO fibroblasts expressing GM-CSF (STO/GM-CSF) or differentiated ES-D3 cells + STO/GM-CSF prior to subcutaneous challenge with LLC cells (0.15 × 10 6 ) at Day 14. Tumor-free mice were challenged again with LLC cells (0.15 × 10 6 ) at day 72. ( B ) The percentages of tumor-free male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender) following the first LLC injection are shown. Log-rank test; Asterisk (*) indicates p < 0.05; Asterisks (**) indicate p < 0.01; Asterisks (***) indicate p < 0.001. ( C ) Kaplan–Meier survival curve demonstrates the probability of survival in male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender). Log-rank test; Asterisks (***) indicate p < 0.001. ( D ) Twenty-eight days after the second LLC challenge, the percentages of tumor-bearing mice in mice immunized with parental ES-D3 cells + STO/GM-CSF (n = 8) or differentiated ES-D3 cells + STO/GM-CSF (n = 2) were determined.

Journal: Scientific Reports

Article Title: The efficacy of an embryonic stem cell-based vaccine for lung cancer prevention depends on the undifferentiated state of the stem cells

doi: 10.1038/s41598-024-83932-0

Figure Lengend Snippet: Differentiation of ES-D3 cells decreases their efficacy to prevent the development of implanted lung tumors. ( A ) The schematic depiction of immunization regimen. Male and female C57BL/6 mice were immunized twice with 1 × PBS (vehicle control), parental ES-D3 cells + STO fibroblasts expressing GM-CSF (STO/GM-CSF) or differentiated ES-D3 cells + STO/GM-CSF prior to subcutaneous challenge with LLC cells (0.15 × 10 6 ) at Day 14. Tumor-free mice were challenged again with LLC cells (0.15 × 10 6 ) at day 72. ( B ) The percentages of tumor-free male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender) following the first LLC injection are shown. Log-rank test; Asterisk (*) indicates p < 0.05; Asterisks (**) indicate p < 0.01; Asterisks (***) indicate p < 0.001. ( C ) Kaplan–Meier survival curve demonstrates the probability of survival in male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender). Log-rank test; Asterisks (***) indicate p < 0.001. ( D ) Twenty-eight days after the second LLC challenge, the percentages of tumor-bearing mice in mice immunized with parental ES-D3 cells + STO/GM-CSF (n = 8) or differentiated ES-D3 cells + STO/GM-CSF (n = 2) were determined.

Article Snippet: Murine fibroblast cell line STO (ATCC # CRL-1503) infected with a replication-defective retrovirus expressing murine GM-CSF cDNA was acquired from Dr. Glenn Dranoff (Novartis Institutes for Biomedical Research; Boston, MA).

Techniques: Control, Expressing, Injection